My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Sun Pharmaceuticals Industries Ltd Research Report - 17th Nov 2016

Pharmaceutical | Published on Nov 17th 2016


Sun Pharma posted numbers better than expected on OPM and net profit front. Sales came in at Rs7,764cr vs. Rs7,800cr expected vs. Rs6,858cr in 2QFY2016, posting a yoy growth of 13.2%. On the operating front, the EBITDA margin came in at 34.3% vs. 30.1% expected and vs. 27.1% in 2QFY2016. Lower expenses during the quarter aided the OPM expansion. Consequently, the Adj. PAT came in at Rs2,235cr vs. Rs1,545cr expected vs. Rs1,029cr in 2QFY2016, a yoy growth of 117.3%. Apart from better than expected OPM, the company also posted higher than expected other income (Rs621cr in 2QFY2017 vs. Rs226cr in 2QFY2016). We maintain our Buy rating on the stock.

Download Full Report


CMP 683
Target Price 847
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others8.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo